Techniques for the analysis of drug samples may be classified into
three categories based on their discriminating power. Table 1 provides
examples of these techniques listed in order of decreasing discriminating
power from A to C.
The Scientific Working Group for the Analysis of Seized Drugs recommends
that laboratories adhere to the following minimum standards:
|
3.1.
|
When a validated Category A technique is incorporated
into an analytical scheme, then at least one other technique
(from either Category A, B, or C) must be used. |
|
|
3.1.1.
|
This combination must identify the specific drug present and
must preclude a false-positive identification. |
|
|
3.1.2.
|
When sample size allows, the second technique should be applied
on a separate sampling for quality assurance reasons. When sample
size is limited, additional measures should be taken to assure
that the results correspond to the correct sample. |
|
|
3.1.3.
|
All Category A techniques must have reviewable data. |
|
3.2. |
When a Category A technique is not used, then
at least three different validated methods must be employed. |
|
|
3.2.1.
|
These in combination must demonstrate the identity of the
specific drug present and must preclude a false-positive identification.
|
|
|
3.2.2.
|
Two of the three methods must be based on uncorrelated techniques
from Category B. |
| |
|
3.2.3.
|
A minimum of two separate samplings should be used in these
three tests. When sample size is limited, additional measures
should be taken to assure that the results correspond to the
correct sample. |
|
|
3.2.4.
|
All Category B techniques must have reviewable data. |
|
3.3.
|
For the use of any method to be considered of
value, test results must be considered positive. Although negative-test
results provide useful information for ruling out the presence
of a particular drug or drug class, these results have no value
toward establishing the forensic identification of a drug. |
|
3.4.
|
In cases where hyphenated techniques are used
(e.g., gas chromatography-mass spectrometry, liquid chromatography-diode
array ultraviolet spectroscopy), they will be considered as
separate techniques if the results from each are used. |
|
3.5.
|
Cannabis exhibits tend to have characteristics that are visually
recognizable. Macroscopic and microscopic examinations of
cannabis will be considered, exceptionally, as uncorrelated
techniques from Category B when observations include documented
details of botanical features. Additional testing must follow
the scheme outlined in Sections 3.1 or 3.2.
For exhibits of cannabis that lack sufficient observable
macroscopic and microscopic botanical detail (e.g., extracts
or residues), D9-tetrahydrocannabinol
(THC), or other cannabinoids must be identified using the
principles set forth in Sections 3.1 and 3.2.
|
| |
3.6.
|
Examples of reviewable data are as follows: |
|
|
3.6.1.
|
Printed spectra, chromatograms, and photographs or photocopies
of thin layer chromatography plates. |
|
|
3.6.2.
|
Contemporaneous, documented peer review for microcrystalline
tests. |
|
|
3.6.3.
|
Recording of detailed descriptions of morphological characteristics
for cannabis (only). |
|
|
3.6.4.
|
Reference to published data for pharmaceutical identifiers. |